FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients

3 months ago 57

The FDA underscored cases including 2 deaths and a termination linked to patients taking semaglutide, which Novo markets arsenic Ozempic and Wegovy.